Presentation (CTI)

OBJECTIVES: Demonstrate the economic impact and epidemiological aspects of coverage of immunobiological therapies with cutaneous involvement in private health insurer in Brazil with 131.000 lives.
METHODS: A 2-years between November/22 and October/24. Diseases analyzed Psoriasis (Pso). Psoriatic Arthritis (PsA), Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS) and Chronic Urticaria (UC). The drugs analyzed are AntiTNFa, AntiInterleukins and JanusKinase Inhibitors. Costs include materials, medications and fees used in therapy sessions. Exchange rate of Brazilian reais to US dollars at the time of the study. (R$6:U$1)
RESULTS: In the financial aspect, we identified an absolute increase of 76% (U$ 141 thousand/month Nov 2022 to 250 thousand/month Oct 2024 in the cost of treating all patients). Average spending per patient per month increased by 7.6% (U$ 1,470 in the 1st quarter to 1,562 in the 6th quarter). Pso and APs had the largest increase in average cost per patient treated. In frequency, a much more relevant increase in patients treated by 60% (99 patients/month in November 2022 to 159 patients/month in October 2024). AD (100%) and Pso (115%) had the largest increase in cases.
CONCLUSIONS: Immune-mediated skin diseases have a high impact in Brazil and worldwide. In the study, the significant increase in prevalence added much more budgetary impact than the increase in the cost of treatments (ratio 6:1). New therapies and more accessible protocols may be the generating factor for the high frequency indicator. In the studied population, the use of Biosimilars and JAKi with a lower average cost compared to AntiIL may have favored better control of the smaller increase in the average cost per patient. From the perspective of population health management, it is necessary to look not only at the price of treatments, but also at epidemiological aspects and their consequences on the financial impact.